The abstract is read at the publisher; the summary is JClub's.
In the multicenter randomized phase III IRMA trial for low-risk invasive breast cancer, 5-year ipsilateral breast tumor recurrence was 1.0% with APBI versus 0.8% with WBI.
- Why it matters: Clinicians need to know whether accelerated partial-breast irradiation can match whole-breast irradiation’s local control while potentially offering a less extensive treatment for low-risk patients.
- What they did: From 2007–2019, 3,309 patients (age ≥49, margins ≥2 mm, tumor diameter ≤3 cm, pN0-1) were randomized 1:1 to WBI or APBI (38.5 Gy in 10 fractions twice daily), with IBTR as the primary endpoint.
- The result: The hazard ratio for APBI versus WBI was 1.18 (90% CI, 0.63 to 2.20), and the upper confidence limit crossed the noninferiority margin, though the absolute 5-year IBTR difference was <0.2%.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.